Research ExplorerPublicationsPolyclonal and convergent antibody response to Ebola virus v...

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV

Standard

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. / Ehrhardt, Stefanie A; Zehner, Matthias; Krähling, Verena; Cohen-Dvashi, Hadas; Kreer, Christoph; Elad, Nadav; Gruell, Henning; Ercanoglu, Meryem S; Schommers, Philipp; Gieselmann, Lutz; Eggeling, Ralf; Dahlke, Christine; Wolf, Timo; Pfeifer, Nico; Addo, Marylyn M; Diskin, Ron; Becker, Stephan; Klein, Florian.

In: NAT MED, Vol. 25, No. 10, 10.2019, p. 1589-1600.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ehrhardt, SA, Zehner, M, Krähling, V, Cohen-Dvashi, H, Kreer, C, Elad, N, Gruell, H, Ercanoglu, MS, Schommers, P, Gieselmann, L, Eggeling, R, Dahlke, C, Wolf, T, Pfeifer, N, Addo, MM, Diskin, R, Becker, S & Klein, F 2019, 'Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV', NAT MED, vol. 25, no. 10, pp. 1589-1600. https://doi.org/10.1038/s41591-019-0602-4

APA

Ehrhardt, S. A., Zehner, M., Krähling, V., Cohen-Dvashi, H., Kreer, C., Elad, N., Gruell, H., Ercanoglu, M. S., Schommers, P., Gieselmann, L., Eggeling, R., Dahlke, C., Wolf, T., Pfeifer, N., Addo, M. M., Diskin, R., Becker, S., & Klein, F. (2019). Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. NAT MED, 25(10), 1589-1600. https://doi.org/10.1038/s41591-019-0602-4

Vancouver

Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. NAT MED. 2019 Oct;25(10):1589-1600. https://doi.org/10.1038/s41591-019-0602-4

Bibtex

@article{099de0f2c5d94be98d28deeab94902ad,
title = "Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV",
abstract = "Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3-15/IGLV1-40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies.",
keywords = "Adult, Antibodies, Neutralizing/immunology, Antibodies, Viral/immunology, Antibody Formation/immunology, B-Lymphocytes/immunology, Ebola Vaccines/administration & dosage, Ebolavirus/immunology, Female, Hemorrhagic Fever, Ebola/immunology, Humans, Immunity, Humoral/immunology, Male, Middle Aged, Vaccination/adverse effects, Vesiculovirus/genetics, Volunteers",
author = "Ehrhardt, {Stefanie A} and Matthias Zehner and Verena Kr{\"a}hling and Hadas Cohen-Dvashi and Christoph Kreer and Nadav Elad and Henning Gruell and Ercanoglu, {Meryem S} and Philipp Schommers and Lutz Gieselmann and Ralf Eggeling and Christine Dahlke and Timo Wolf and Nico Pfeifer and Addo, {Marylyn M} and Ron Diskin and Stephan Becker and Florian Klein",
year = "2019",
month = oct,
doi = "10.1038/s41591-019-0602-4",
language = "English",
volume = "25",
pages = "1589--1600",
journal = "NAT MED",
issn = "1078-8956",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV

AU - Ehrhardt, Stefanie A

AU - Zehner, Matthias

AU - Krähling, Verena

AU - Cohen-Dvashi, Hadas

AU - Kreer, Christoph

AU - Elad, Nadav

AU - Gruell, Henning

AU - Ercanoglu, Meryem S

AU - Schommers, Philipp

AU - Gieselmann, Lutz

AU - Eggeling, Ralf

AU - Dahlke, Christine

AU - Wolf, Timo

AU - Pfeifer, Nico

AU - Addo, Marylyn M

AU - Diskin, Ron

AU - Becker, Stephan

AU - Klein, Florian

PY - 2019/10

Y1 - 2019/10

N2 - Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3-15/IGLV1-40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies.

AB - Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other Ebolavirus species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3-15/IGLV1-40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies.

KW - Adult

KW - Antibodies, Neutralizing/immunology

KW - Antibodies, Viral/immunology

KW - Antibody Formation/immunology

KW - B-Lymphocytes/immunology

KW - Ebola Vaccines/administration & dosage

KW - Ebolavirus/immunology

KW - Female

KW - Hemorrhagic Fever, Ebola/immunology

KW - Humans

KW - Immunity, Humoral/immunology

KW - Male

KW - Middle Aged

KW - Vaccination/adverse effects

KW - Vesiculovirus/genetics

KW - Volunteers

U2 - 10.1038/s41591-019-0602-4

DO - 10.1038/s41591-019-0602-4

M3 - SCORING: Journal article

C2 - 31591605

VL - 25

SP - 1589

EP - 1600

JO - NAT MED

JF - NAT MED

SN - 1078-8956

IS - 10

ER -